26 Biotechnology Stocks to Sell Now

This week, 26 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Puma Biotechnology, Inc. (PBYI) slips from a D to a F this week. Puma Biotechnology, Inc. engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of PBYI stock.

This week, bluebird bio, Inc.’s (BLUE) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of BLUE stock.

Slipping from a D to a F rating, Agios Pharmaceuticals, Inc. (AGIO) takes a hit this week. The company also gets F’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

PTC Therapeutics, Inc. (PTCT) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTCT stock.

This week, Otonomy, Inc. (OTIC) drops from a C to a D rating. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of OTIC stock.

Esperion Therapeutics, Inc. (ESPR) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ESPR stock.

Bellicum Pharmaceuticals Inc (BLCM) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

Immune Design Corp’s (IMDZ) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

Ardelyx, Inc. (ARDX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ARDX stock.

This is a rough week for Dicerna Pharmaceuticals, Inc. (DRNA). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRNA stock.

TG Therapeutics, Inc. (TGTX) declines this week from a C to a D. TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TGTX stock.

Exact Sciences Corporation (EXAS) gets weaker ratings this week as last week’s D drops to a F. Exact Sciences Corporation is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

This week, Arrowhead Research Corporation’s (ARWR) rating worsens to a D from the company’s C rating a week ago. Arrowhead Research Corporation a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARWR stock.

Arbutus Biopharma Corporation (ABUS) slips from a D to a F this week. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of ABUS stock.

This is a rough week for EPIRUS Biopharmaceuticals, Inc. (EPRS). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

Slipping from a D to a F rating, QLT Inc. (QLTI) takes a hit this week. QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of QLTI stock.

Immunomedics, Inc. (IMMU) earns a D this week, moving down from last week’s grade of C. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMU stock.

GenVec, Inc.’s (GNVC) rating weakens this week, dropping to a D versus last week’s C. GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of GNVC stock.

Arena Pharmaceuticals, Inc. (ARNA) declines this week from a D to a F. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARNA stock.

Celladon Corporation (CLDN) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Bioline RX Ltd Sponsored ADR (BLRX) is having a tough week. The company’s rating falls from a C to a D. Bioline RX Ltd Sponsored ADR a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLRX stock.

This week, Peregrine Pharmaceuticals, Inc. (PPHM) drops from a C to a D rating. Peregrine Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PPHM stock.

Neuralstem, Inc. (CUR) slips from a D to a F this week. Neuralstem, Inc. is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the central nervous system. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CUR stock.

This is a rough week for Rosetta Genomics Ltd (ROSG). The company’s rating falls to F from the previous week’s D. Rosetta Genomics Ltd is a biomedical company that discovers and develops diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ROSG stock.

This week, OncoGenex Pharmaceuticals, Inc. (OGXI) drops from a C to a D rating. OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OGXI stock.

Pluristem Therapeutics Inc. (PSTI) earns a F this week, moving down from last week’s grade of D. Pluristem Therapeutics Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PSTI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/01/26-biotechnology-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC